Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis

A number of approved treatment options currently exist for BRAF-mutant patients with unresectable or metastatic melanoma (MM), and effective diagnosis tools are available for assessing BRAF mutational status [1 –3]. Clinician judgment drives individualized treatment decisions based on characteristics of the patient and of the disease [4]. Since multiple options exist, it is essential that treatment decisions are informed by relevant and contemporary clinical research, including efficacy and safety data.

Source: Cancer Treatment Reviews - September 5, 2022 Category: Cancer & Oncology Authors: Corrie Pippa, Meyer Nicolas, Berardi Rossana, Guidoboni Massimo, Schlueter Maximilian, Kolovos Spyros, Macabeo B érengère, Trouiller Jean-Baptiste, Laramée Philippe Source Type: research